Modulators of HIF1α and NFkB in cancer treatment: Is it a rational approach for controlling malignant progression?

Frontiers in Pharmacology

Volumn 4 FEB, Issue , 2013, Pages

  Tafani, Marco ^a,b   Pucci, Bruna ^b   Russo, Andrea ^c   Schito, Luana ^d   Pellegrini, Laura ^b,e   Perrone, Giulietta A ^f   Villanova, Lidia ^b,g   Salvatori, Luisa ^h   Ravenna, Linda ^h   Petrangeli, Elisa ^a,h   Russo, Matteo A ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f SAN FILIPPO NERI HOSPITAL   (Italy)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CNR   (Italy)

Author keywords

Cancer; HIF1 inhibitors; Hypoxia; Inflammation; NFkB inhibitors; Sirtuin activators

Indexed keywords

ACRIFLAVINE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BORTEZOMIB; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CHETOMIN; CYTOKINE; CYTOKINE RECEPTOR; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; ECHINOMYCIN; GALLIC ACID; GELDANAMYCIN; GELDANAMYCIN DERIVATIVE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SIRTUIN; SUPPRESSOR OF CYTOKINE SIGNALING; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADAPTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL ADHESION; CELL MIGRATION; DNA BINDING; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HYPOXIA; INFLAMMATION; INFLAMMATORY REPARATIVE RESPONSE; MALIGNANT TRANSFORMATION; METABOLISM; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; P2X7 GENE; PROTEIN FUNCTION; RAGE GENE; REVIEW; TLR GENE; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; VON HIPPEL LINDAU DISEASE;

EID: 84876569908     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00013     Document Type: Review

References (101)

1. Ahluwalia, A., and Tarnawski, A. S. (2012). Critical role of hypoxia sensor-HIF-1a in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr. Med. Chem. 19, 90-97.
2. Befani, C. D., Vlachostergios, P. J., Hatzidaki, E., Patrikidou, A., Bonanou, S., Simos, G., et al. (2012). Bortezomib represses HIF-1a protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med. 90, 45-54.
3. Brahimi-Horn, M. C., Chiche, J., and Pouysségur, J. (2007). Hypoxia and cancer. J. Mol. Med. 85, 1301-1307.
4. Chen, L. F., and Greene, W. C. (2004). Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 5, 392-401.
5. Choi, H., Chun, Y. S., Kim, S. W., Kim, M. S., and Park, J. W. (2006). Curcumin inhibits hypoxia inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol. 70, 1664-1671.
6. Choi, K. C., Lee, Y. H., Jung, M. G., Kwon, S. H., Kim, M. J., Jun, W. J., et al. (2009). Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol. Cancer Res. 7, 2011-2021.
7. Choi, Y. J., Choi, H., Cho, C. H., and Park, J. W. (2011a). Red ginseng deregulates hypoxia-induced genes by dissociating the HIF-1 dimer. J. Nat. Med. 65, 344-352.
8. Choi, J. Y., Jang, Y. S., Min, S. Y., and Song, J. Y. (2011b). Overexpression of MMP-9 and HIF-1a in breast cancer cells under hypoxic conditions. J. Breast Cancer 14, 88-95.
9. Chung, S., Yao, H., Caito, S., Hwang, J. W., Arunachalam, G., and Rahman, I. (2010). Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys. 501, 79-90.
10. Coleman, R., Gnant, M., Morgan, G., and Clezardin, P. (2012). Effects of bone-targeted agents on cancer progression and mortality. J. Natl. Cancer Inst. 104, 1059-1067.
11. Dallas, C., Gerbi, A., Tenca, G., Juchaux, F., and Bernard, F. X. (2008). Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE). Phytomedicine 15, 783-792.
12. Dat, N. T., Jin, X., Lee, J. H., Lee, D., Hong, Y. S., Lee, K., et al. (2007). Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J. Nat. Prod. 70, 1093-1097.
13. Dat, N. T., Jin, X., Lee, K., Hong, Y. S., Kim, Y. H., and Lee, J. J. (2009). Hypoxia-inducible factor-1 inhibitory benzofurans and chalcone-derived diels-alder adducts from Morus species. J. Nat. Prod. 72, 39-43.
14. De Santis, E., Di Vito, M., Perrone, G. A., Mari, E., Osti, M., De Antoni, E., et al. (2013). Overexpression of pro-inflammatory genes and down-regulation of SOCS-1 in human PTC and in hypoxic BCPAP cells. Biomed. Pharmacother. 67, 7-16.
15. DiDonato, J. A., Mercurio, F., and Karin, M. (2012). NF-κB and the link between inflammation and cancer. Immunol. Rev. 246, 379-400.
16. Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., et al. (2001). Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-65.
17. Fer, N., and Melillo, G. (2011). The HIF-1a-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper. Cell Cycle 10, 3228.
18. Finley, L. W., Carracedo, A., Lee, J., Souza, A., Egia, A., Zhang, J., et al. (2011). SIRT3 opposes reprogramming of cancer cell metabolism through HIF1a destabilization. Cancer Cell 19, 416-428.
19. Furuta, E., Okuda, H., Kobayashi, A., and Watabe, K. (2010). Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta 1805, 141-152.
20. Gertz, M., Nguyen, G. T., Fischer, F., Suenkel, B., Schlicker, C., Fränzel, B., et al. (2012). A molecular mechanism for direct sirtuin activation by resveratrol. PLoS ONE 7:e49761. doi:10.1371/journal.pone.0049761
21. Gray S G, and Teh, B T (2001) Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr Mol Med 1, 401-429
22. Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., et al. (2008). A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7, 3598-3608.
23. Grynkiewicz, G., and Slifirski, P. (2012). Curcumin and curcuminoids in quest for medicinal status. Acta Biochim. Pol. 59, 201-212.
24. Guan, J. Z., Guan, W. P., Maeda, T., and Makino, N. (2012). Different levels of hypoxia regulate telomere length and telomerase activity. Aging Clin. Exp. Res. 24, 213-217.
25. Gunn, E. J., Williams, J. T., Huynh, D. T., Iannotti, M. J., Han, C., Barrios, F. J., et al. (2011). The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma. Leuk. Lymphoma 52, 1085-1097.
26. Gupta, S. C., Sundaram, C., Reuter, S., and Aggarwal, B. B. (2010). Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta 1799, 775-787.
27. Gustafson-Svärd, C., Lilja, I., Hallböök, O., and Sjödahl, R. (1997). Cyclo-oxygenase and colon cancer: clues to the aspirin effect? Ann. Med. 29, 247-252.
28. Hanahan, D., and Coussens, L. M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322.
29. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
30. Hao, N. B., Lü, M. H., Fan, Y. H., Cao, Y. L., Zhang, Z. R., and Yang, S. M. (2012). Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 948098.
31. Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., et al. (2008). The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10, 1349-1355.
32. Hossain, C. F., Kim, Y. P., Baerson, S. R., Zhang, L., Bruick, R. K., Mohammed, K. A., et al. (2005). Saururus cernuus lignans-potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem. Biophys. Res. Commun. 333, 1026-1033.
33. Houtkooper, R. H., Pirinen, E., and Auwerx, J. (2012). Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225-238.
34. Huang, J., Plass, C., and Gerhauser, C. (2011). Cancer chemoprevention by targeting the epigenome. Curr. Drug Targets 12, 1925-1956.
35. Ince, T. A., Richardson, A. L., Bell, G. W., Saitoh, M., Godar, S., Karnoub, A. E., et al. (2007). Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12, 160-170.
36. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. (2002). Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 77, 29936-29944.
37. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12, 363-369.
38. Jin, S., Mutvei, A. P., Chivukula, I. V., Andersson, E. R., Ramsköld, D., Sandberg, R., et al. (2012). Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKa/IKKß. Oncogene. doi:10.1038/onc.2012.517
39. Kale, A. J., and Moore, B. S. (2012). Molecular mechanisms of acquired proteasome inhibitor resistance. J. Med. Chem.55, 10317-10327.
40. Karin, M., Yamamoto, Y., and Wang, Q. M. (2004). The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17-26.
41. Kast, R. E. (2006). Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha. Inflammopharmacology 14, 256-259.
42. Kawahara, T. L., Michishita, E., Adler, A. S., Damian, M., Berber, E., Lin, M., et al. (2009). SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 136, 62-74.
43. Kiernan, R., Brès, V., Ng, R. W., Coudart, M. P., El Messaoudi, S., Sardet, C., et al. (2003). Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278, 2758-2766.
44. Kozakai, N., Kikuchi, E., Hasegawa, M., Suzuki, E., Ide, H., Miyajima, A., et al. (2012). Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br. J. Cancer 107, 652-657.
45. Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., et al. (2004). Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6, 33-43.
46. Laemmle, A., Lechleiter, A., Roh, V., Schwarz, C., Portmann, S., Furer, C., et al. (2012). Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1a protein under hypoxic conditions. PLoS ONE 7:e33433. doi:10.1371/journal.pone.0033433
47. Lam W, Bussom, S, and Cheng, Y C (2009) Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma Mol Cancer Ther 8, 415-423
48. Langley, R. R., and Fidler, I. J. (2011). The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 128, 2527-2535.
49. Larsson, L. G. (2011). Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin. Cancer Biol. 21, 367-376.
50. Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., and Semenza, G. L. (2009). Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. U.S.A. 106, 17910-17915.
51. Lee, S. W., Jeong, H. K., Lee, J. Y., Yang, J., Lee, E. J., Kim, S. Y., et al. (2012). Hypoxic priming of mESCs accelerates vascular-lineage differentiation through HIF1-mediated inverse regulation of Oct4 and VEGF. EMBO Mol. Med. 4, 924-938.
52. Lim, J. H., Lee, Y. M., Chun, Y. S., Chen, J., Kim, J. E., and Park, J. W. (2010). Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell 38, 864-878.
53. Liu, J. L., Ma, H. P., Lu, X. L., Sun, S. H., Guo, X., and Li, F. C. (2011). NF-κB induces abnormal centrosome amplification by upregulation of CDK2 in laryngeal squamous cell cancer. Int. J. Oncol. 39, 915-924.
54. Liu, Y., Veena, C. K., Morgan, J. B., Mohammed, K. A., Jekabsons, M. B., Nagle, D. G., et al. (2009). Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. J. Biol. Chem. 284, 5859-5868.
55. Lu, X., and Kang, Y. (2010). Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 16, 5928-5935.
56. Lubbad, A., Oriowo, M. A., and Khan, I. (2009). Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol. Cell. Biochem. 322, 127-135.
57. Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., et al. (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375.
58. Maeda, M., Hasebe, Y., Egawa, K., Shibanuma, M., and Nose, K. (2006). Inhibition of angiogenesis and HIF-1alpha activity by antimycin A1. Biol. Pharm. Bull. 29, 1344-1348.
59. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601.
60. Marcu, K. B., Otero, M., Olivotto, E., Borzi, R. M., and Goldring, M. B. (2010). NF-kappaB signaling: multiple angles to target OA. Curr. Drug Targets 11, 599-613.
61. Maugeri-Saccà, M., Vigneri, P., and De Maria, R. (2011). Cancer stem cells and chemosensitivity. Clin. Cancer Res. 17, 4942-4947.
62. Micalizzi, D. S., Farabaugh, S. M., and Ford, H. L. (2010). Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J. Mammary Gland Biol. Neoplasia 15, 117-134.
63. Morris, B. J. (2012). Seven sirtuins for seven deadly diseases of aging. Free Radic. Biol. Med. doi:10.1016/j.freeradbiomed.2012.10.525 [pii: S0891-5849(12)01756-X].
64. Mucaj, V., Shay, J. E., and Simon, M. C. (2012). Effects of hypoxia and HIFs on cancer metabolism. Int. J. Hematol.95, 464-470
65. Muratori, C., and Tamagnone, L. (2012). Semaphorin signals tweaking the tumor microenvironment. Adv. Cancer Res. 114, 59-85.
66. Nasr, Z., and Pelletier, J. (2012). Tumor progression and metastasis: role of translational deregulation. Anticancer Res. 32, 3077-3084.
67. Noman, M. Z., Messai, Y., Carré, T., Akalay, I., Méron, M., Janji, B., et al. (2011). Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit. Rev. Immunol. 31, 357-377.
68. Ono, M. (2008). Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 99, 1501-1506.
69. Palayoor, S. T., Tofilon, P. J., and Coleman, C. N. (2003). Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin. Cancer Res. 9, 3150-3157.
70. Park, S. Y., Jeong, K. J., Lee, J., Yoon, D. S., Choi, W. S., Kim, Y. K., et al. (2007). Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett. 258, 63-69.
71. Pellegrini, L., Pucci, B., Villanova, L., Marino, M. L., Marfe, G., Sansone, L., et al. (2012). SIRT3 protects from hypoxia and staurosporine-mediated cell death by maintaining mitochondrial membrane potential and intracellular pH. Cell Death Differ. 19, 1815-1825.
72. Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M., Carducci, M. A., Atadja, P., et al. (2006). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 66, 8814-8821.
73. Qiang, L., Wu, T., Zhang, H. W., Lu, N., Hu, R., Wang, Y. J., et al. (2012). HIF-1a is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 19, 284-294.
74. Rothgiesser, K. M., Erener, S., Waibel, S., Lüscher, B., and Hottiger, M. O. (2010). SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys310. J. Cell. Sci. 123, 4251-4258.
75. Schito, L., Rey, S., Tafani, M., Zhang, H., Wong, C. C., Russo, A., et al. (2012). Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 109, E2707-E2716.
76. Schug, T. T., Xu, Q., Gao, H., Peres-da-Silva, A., Draper, D. W., Fessler, M. B., et al. (2010). Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol. 30, 4712-4721.
77. Semenza, G. L. (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207-214.
78. Semenza, G. L., Jiang, B. H., Leung, S. W., Passantino, R., Concordet, J. P., Maire, P., et al. (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529-32537.
79. Shay, J. E., and Celeste Simon, M. (2012). Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Semin. Cell Dev. Biol. 23, 389-394.
80. Sreenivasan, Y., Sarkar, A., and Manna, S. K. (2003). Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation. Oncogene 22, 4356-4369.
81. Strebovsky, J., Walker, P., and Dalpke, A. H. (2012). Suppressor of cytokine signaling proteins as regulators of innate immune signaling. Front. Biosci. 17, 1627-1639.
82. Sun, Y. X., Dai, D. K., Liu, R., Wang, T., Luo, C. L., Bao, H. J., et al. (2012). Therapeutic effect of SN50, an inhibitor of nuclear factor-?B, in treatment of TBI in mice. Neurol. Sci. PMID: 22437493 [Epub ahead of print].
83. Tafani M, Schito, L, Pellegrini, L, Villanova, L, Marfe, G, Anwar, T, et al (2011a) Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B Carcinogenesis 32, 1167-1175
84. Tafani, M., Di Vito, M., Frati, A., Pellegrini, L., De Santis, E., Sette, G., et al. (2011b). Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J. Neuroinflammation 8, 32.
85. Tanaka, T., Yamaguchi, J., Shoji, K., and Nangaku, M. (2012). Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host. J. Biol. Chem. 287, 34866-34882.
86. Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., et al. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14, 612-622.
87. Tobar, N., Villar, V., and Santibanez, J. F. (2010). ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol. Cell. Biochem. 340, 195-202.
88. Toffoli, S., and Michiels, C. (2008). Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumors. FEBS J. 275, 2991-3002.
89. Traugott, A. L., and Moley, J. F. (2010). The RET protooncogene. Cancer Treat. Res. 153, 303-319.
90. Vanden Berghe, W. (2012). Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol. Res. 65, 565-576.
91. Vanden Berghe, W., Plaisance, S., Boone, E., De Bosscher, K., Schmitz, M. L., Fiers, W., et al. (1998). p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273, 3285-3290.
92. Villalba, J. M., and Alcaín, F. J. (2012). Sirtuin activators, and inhibitors. Biofactors 38, 349-359.
93. Wang, D., and Dubois, R. N. (2006). Prostaglandins and cancer. Gut 55, 115-122.
94. Wang, Y., Liu, Y., Malek, S. N., Zheng, P., and Liu, Y. (2011). Targeting HIF1a eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8, 399-411.
95. Wilczynski, J., Duechler, M., and Czyz, M. (2011). Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I. Arch. Immunol. Ther. Exp. (Warsz.) 59, 289-299.
96. Xia, Y., Choi, H. K., and Lee, K. (2012). Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem. 49, 24-40.
97. Yao, J., Hu, R., Sun, J., Lin, B., Zhao, L., Sha, Y., et al. (2012). Oroxylin A prevents inflammation-related tumor through down-regulation of inflammatory gene expression by inhibiting NF-κB signaling. Mol. Carcinog. doi:10.1002/mc.21958
98. Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., et al. (2008). Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. U.S.A.,105, 19579-19586
99. Zhong, L., D'Urso, A., Toiber, D., Sebastian, C., Henry, R. E., Vadysirisack, D. D., et al. (2010). The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140, 280-293.
100. Zhu, P., Ning, Y., Yao, L., Chen, M., and Xu, C. (2010). The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J. Exp. Clin. Cancer Res. 29, 124.
101. Zigler, M., Dobroff, A. S., and Bar-Eli, M. (2010). Cell adhesion: implication in tumor progression. Minerva Med. 101, 149-162.